While our model is not dependent upon AR signaling for growth, our immunologic findings are congruent with clinical findings that have failed to demonstrate robust levels of infiltrating cytotoxic T cells in most prostate cancers [27], as well as a lack of clinical response to PD1 and PDL1 immune checkpoint inhibitors [28,29,30]. This evidence concerns the gene CD274 and prostate carcinoma.